

1 **Univariable and multivariable Mendelian randomization study**
2 **identified the key role of gut microbiota in immunotherapeutic**
3 **toxicity**

4
5 **Baike Liu^{1,2,5}, Zheran Liu^{3,5}, Tianxiang Jiang^{1,2,5}, Xiangshuai Gu⁴, Xiaonan Yin^{1,2},**
6 **Zhaolun Cai^{1,2}, Xiaoqiao Zou^{1,2}, Lei Dai^{4*}, Bo Zhang^{1,2*}**

7
8 ¹ Department of General Surgery, West China Hospital, Sichuan University, Chengdu,
9 Sichuan, 610041, the People's Republic of China.

10 ² Gastric Cancer Center, West China Hospital, Sichuan University. Chengdu, Sichuan,
11 610041, the People's Republic of China.

12 ³ Department of Biotherapy and National Clinical Research Center for Geriatrics,
13 Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, the
14 People's Republic of China.

15 ⁴ State Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
16 Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu,
17 Sichuan, 610041, the People's Republic of China.

18 ⁵ These authors contributed equally: Baike Liu, Zheran Liu, Tianxiang Jiang.

19 *e-mail: zhangbo_scu@scu.edu.cn, daileisklb2012@163.com

20
21
22 Running title: Causal associations between gut microbiota and irAEs

33 **Abstract:**

34 **Background:** In cancer patients receiving immune checkpoint inhibitors (ICIs), there
35 is emerging evidence suggesting a correlation between gut microbiota and
36 immune-related adverse events (irAEs). However, the exact roles of gut microbiota
37 and the causal associations are yet to be clarified.

38 **Methods:** To investigate this, we first conducted a univariable bi-directional
39 two-sample Mendelian randomization (MR) analysis. Instrumental variables (IVs) for
40 gut microbiota were retrieved from the MiBioGen consortium (18,340 participants).
41 GWAS summary data for irAEs were gathered from an ICIs-treated cohort with 1,751
42 cancer patients. Various MR analysis methods, including Inverse variance weighted
43 (IVW), MR PRESSO, maximum likelihood (ML), weighted median, weighted mode,
44 and cML-MA-BIC were used. Furthermore, multivariable MR (MVMR) analysis was
45 performed to account for possible influencing instrumental variables.

46 **Results:** Our analysis identified fourteen gut bacterial taxa that were causally
47 associated with irAEs. Notably, *Lachnospiraceae* was strongly associated with an
48 increased risk of both high-grade and all-grade irAEs, even after accounting for the
49 effect of BMI in the MVMR analysis. *Akkermansia*, *Verrucomicrobiaceae*, and
50 *Anaerostipes* were found to exert protective roles in high-grade irAEs. However,
51 *Ruminiclostridium6*, *Coprococcus3*, *Collinsella*, and *Eubacterium (fissicatena group)*
52 were associated with a higher risk of developing high-grade irAEs.
53 *RuminococcaceaeUCG004*, and *DefluviitaleaceaeUCG011* were protective against
54 all-grade irAEs, whereas *Porphyromonadaceae*, *Roseburia*, *Eubacterium (brachy*
55 *group)*, and *Peptococcus* were associated with an increased risk of all-grade irAEs.

56 **Conclusion:** Our analysis highlights a strong causal association between
57 *Lachnospiraceae* and irAEs, along with some other gut microbial taxa. These findings
58 provide potential modifiable targets for managing irAEs and warrant further
59 investigation.

60

61 **Key words:** Gut microbiota, Immunotherapy toxicity, Immune-related adverse effects,
62 irAEs, *Lachnospiraceae*, *Akkermansia*, *Ruminiclostridium6*, Mendelian
63 randomization study, multivariable Mendelian randomization study, MVMR

64

65

66

67

68

69 **Introduction**

70 Applications of immune checkpoint inhibitors (ICIs), especially those targeting
71 CTLA-4 and PD-1/PD-L1, have revolutionized the treatment of various aggressive
72 cancers (1). By blocking inhibitory signaling pathways and reinvigorating the natural
73 anti-tumor immune response, these inhibitors have significantly prolonged the lives of
74 numerous cancer patients (2–5). However, due to the inhibition of the systemic brake
75 of immune activation, ICIs can cause off-target effects resulting in immune-mediated
76 toxicities to organs and non-malignant tissues. This newly emerging registry of
77 iatrogenic effects, known as immune-related adverse events (irAEs), usually resemble
78 autoimmune disorders, such as colitis, dermatitis, and thyroiditis (6). Although the
79 majority of irAEs manifest in a mild manner, still, up to 55% of patients develop
80 serious irAEs in combined therapy (anti-CTLA-4 and anti-PD-1) (7). Notably, serious
81 irAEs pose significant risks to patients' well-being and may result in morbidity and
82 mortality, not only due to the adverse event itself but also due to the need to suspend
83 or terminate ICIs therapy and the potential impairment of the ICIs-induced immune
84 response while using immunosuppressants (e.g. corticosteroids) (8–10). Therefore,
85 effective management of irAEs is critical to optimize the safety and efficacy of ICIs
86 therapy.

87 The precise mechanisms underlying irAEs are not fully understood, but
88 emerging evidence indicates that the gut microbiota, a complex and dynamic system
89 of microorganisms colonizing the intestinal tract, may play a crucial role in the
90 regulation of irAEs. Simpson et al. found a reduced alpha-diversity of intestinal
91 microbiota in patients who developed severe irAEs (11). Furthermore, antibiotics
92 commonly prescribed prophylactically to hospitalized patients have been shown to
93 increase the risk of ICIs therapy-related irAEs that are not limited to the
94 gastrointestinal tract (12–14). The gut microbiota closely interacts with the host
95 immune system and has been implicated in the regulation of various autoimmune and
96 inflammatory disorders (15,16). However, consensus on the core microbial drivers or
97 protective microbes of irAEs is still lacking, due to inconsistent findings reported in
98 previous studies (11,17–19). The discrepancies among previous studies may be
99 attributed to limited sample sizes and susceptibility to confounding factors such as age,
100 diet, and medication usage in observational designs (11,20).

101 Mendelian randomization (MR), initially described by Katan in 1986 (21), is a
102 novel method for inferring causal associations between modifiable risk factors and
103 health outcomes using genetic variations as instrumental variables (IVs) (22). MR
104 effectively addresses the limitations of confounding and measurement errors that
105 often exist in observational studies, as the direction of causation is from the genetic
106 polymorphism to the trait of interest, not vice versa (23). Therefore, we aim to utilize

107 MR, an increasingly popular method in drug discovery and epidemiology (24,25), to
108 investigate the potential association between the gut microbiota and irAEs, providing
109 further evidence for the management of irAEs by manipulating human gut microbiota.
110

111 **2. Methods**

112 **Study design and data source**

113 An overview of the study design was illustrated in **Figure 1**. In general, we first
114 performed univariable bi-directional two-sample MR analysis, which utilizes single
115 nucleotide polymorphisms (SNPs) from summary-level data as proxies for the risk
116 factor under investigation. Then, several sensitivity analyses and multivariable MR
117 analysis (MVMR) was conducted to further increase the robustness of our study. To
118 ensure the validity of the MR results, three assumptions needed to be satisfied, as
119 illustrated in **Figure S1** (22):

120 (1) **Relevance assumption:** The genetic variants should demonstrate a strong
121 association with the exposure;

122 (2) **Independence assumption:** The genetic variants should not be associated
123 with any confounders that could affect the relationship between the exposure and
124 outcome;

125 (3) **Exclusion restriction assumption:** The genetic variants should not have an
126 independent effect on the outcome aside from their impact through the exposure.

127 This study is based on publicly available GWAS summary statistics and ethical
128 approvals were acquired by the original studies.

129

130 **Gut microbiota:** Genetic variations associated with the composition of gut
131 microbiota were derived from the most comprehensive genome-wide meta-analysis
132 conducted to date by the MiBioGen consortium (26). This study included a total of
133 18,340 individuals from 24 cohorts worldwide, mainly of European descent ($n =$
134 13,266). Fecal DNA was extracted, and targeted sequencing of variable regions in the
135 bacterial 16S rRNA gene (V4, V3-V4, and V1-V2 regions) was performed to profile
136 the gut bacterial composition. To account for sequencing depth differences across
137 cohorts, all cohorts were rarefied to 10,000 reads per sample. Taxonomic
138 classification was performed using direct taxonomic binning method (26). Following
139 quality control, imputation, and post-imputation filtering procedures, gut bacterial
140 taxa observed in over 10% of samples were included in the microbiota quantitative
141 trait loci (mbQTL) mapping (26). This allowed us to identify host genetic variants
142 associated with the relative abundance of bacterial taxa. Further details on microbial
143 data processing can be found in the original study. Genus-level and family-level taxa
144 were included in our analysis, resulting in a total of 131 genus-level and 35

145 family-level taxa.

146

147 **irAEs:** Summary-level data of irAEs was obtained from a recent GWAS
148 conducted in the Dana-Farber Cancer Institute (DFCI) cohort (27). The study included
149 1,751 cancer patients of European ancestry who underwent ICIs treatments between
150 2013 and 2020. The majority of patients (approximately 90%) received PD-1/PD-L1
151 inhibitors, while the remaining 10% received combined immunotherapy (CTLA4 and
152 PD-1/PD-L1 inhibitors). Among the 1,751 cancer patients, 259 cases that experienced
153 high-grade irAEs (grade 3 to 5 events) were manually curated according to the
154 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events
155 v.5 guidelines. Additionally, algorithm-based autoimmune-like electronic health
156 records were used to identify 339 patients who experienced any grade irAEs (referred
157 to as all-grade irAEs). Most of these cases were grade 2 or higher events (27). The
158 tumor tissue of these patients was sequenced using the targeted OncoPanel
159 sequencing platform. After quality control steps, germline SNPs were imputed by
160 utilizing ultra-low-coverage off-target reads. Then, the GWAS was conducted in the
161 DFCI cohort to investigate the association of all variants with the time from the start
162 of ICIs treatment to the occurrence of the two phenotypes of irAEs. For more detailed
163 information, please refer to the original publication (27).

164

165 **Selection of instrumental variables**

166 Several steps were followed in the selection of iVs. Firstly, for the gut
167 microbiome, we selected SNPs associated with bacterial taxa with a p-value less than
168 1×10^{-5} for further analysis (28,29). Secondly, potential SNPs were clumped for
169 independence in the TwoSampleMR package in R software. We used the European
170 1000 Genomes Project Phase 3 reference panel and set the linkage-disequilibrium
171 threshold (r^2) at 0.001 within a 10 Mb window size. Thirdly, we extracted SNPs from
172 the outcome statistics and performed a harmonization procedure. SNPs that were not
173 available in the outcome GWAS data were replaced with proxy SNPs ($r^2 > 0.8$), and
174 palindromic SNPs were removed for further MR analysis. Furthermore, F statistics of
175 selected iVs, which indicate instrument strength, was calculated as $[\text{Beta}/\text{SE}]^2$.
176 Typically, F statistics > 10 suggest enough iVs strength to avoid weak instrument bias
177 (30). Finally, All SNPs with positive results were re-examined using PhenoScanner
178 package (version 1.0) in R software to investigate the presence of potential
179 confounders. Bacterial taxa with less than 3 valid SNPs and unknown origin were
180 excluded from the analysis to mitigate potential bias. Consequently, we included a
181 total of 104 genus-level and 28 family-level bacterial taxa ($n = 132$) for further MR
182 analysis.

183

184 **Statistical analysis**

185 In this study, we employed several MR analysis methods to explore the potential
186 causal relationship between gut microbiota and irAEs. The methods used included
187 IVW, MR PRESSO, ML, weighted median, weighted mode, and a constrained
188 maximum likelihood and model averaging based method (cML-MA-BIC). IVW and
189 MR PRESSO were used in the primary analysis. In general, IVW provides maximum
190 statistical power when all instruments are valid (31), while MR PRESSO identifies
191 and removes genetic variants that deviate significantly from the variant-specific
192 causal estimates of other variants, thereby increasing statistical power and addressing
193 potential outliers (32). The ML method resembles the IVW approach which assumes
194 the absence of both heterogeneity and horizontal pleiotropy. If these assumptions hold
195 true, the ML method yields unbiased results with smaller standard errors compared to
196 the IVW approach (33). Considering the potential existence of IV pleiotropy, we also
197 performed pleiotropy-robust methods including weighted median, weighted mode,
198 and cML-MA-BIC in the sensitivity analysis. These methods relax the instrumental
199 variable assumptions. Weighted median were introduced when the exclusion
200 restriction assumption was violated (uncorrelated pleiotropy), which typically assume
201 fewer than 50% of genetic variants are invalid (34). The weighted-mode method
202 clusters genetic variants based on their similarity in causal effect and estimates the
203 overall causal effect based on the cluster with the most number of iVs (35). The
204 cML-MA-BIC method is a novel approach developed for MR analysis, specifically
205 addressing the issue of invalid iVs exhibiting both uncorrelated and correlated
206 pleiotropy (violation of the independence assumption) (36). By being robust to such
207 violations, cML-MA-BIC improves the accuracy of MR analysis, reduces Type I error,
208 and increases statistical power (36).

209 Next, heterogeneity and directional pleiotropy were assessed using Cochra's Q
210 statistics and MR Egger intercept. Leave-one-out (LOO) analysis was conducted to
211 identify possible reliance on a specific variant, which involved excluding one SNP at
212 a time for all valid SNPs in the IVW analysis. Additionally, reverse MR analysis
213 between irAEs and the identified significant gut bacterial taxa was performed.
214 Moreover, MVMR analysis, which could help us better understand the intricate
215 interplay between the risk factors was further conducted (37). We considered a
216 Bonferroni-corrected p-value of 3.89×10^{-4} (0.05/132) as the significance threshold
217 for gut microbiota. Two-tailed p-value < 0.05 was considered suggestive of
218 significance. All analyses were conducted using R packages "TwoSampleMR"
219 (version 0.5.6), "MRPRESSO" (version 1.0), and "MRcML" (version 0.0.0.9) in R
220 software (version 4.2.2).

221

222 **3. Results**

223 **3.1 Genetic instruments and primary MR analysis**

224 A total of 870 single nucleotide polymorphisms (SNPs) were selected as
225 instrumental variables (iVs) for the 132 gut bacterial taxa (**Table S1**). The F statistics
226 for each SNP ranged from 16.91 to 36.57, with a median value of 21.66. Using the
227 IVW and MR-PRESSO methods, eight gut bacterial taxa associated with high-grade
228 irAEs were identified with p-values < 0.05. These taxa include *Lachnospiraceae*,
229 *Verrucomicrobiaceae*, *Ruminiclostridium6*, *Coprococcus3*, *Anaerostipes*,
230 *Akkermansia*, *Collinsella*, and *Eubacterium (fissicatena group)*. For all-grade irAEs,
231 seven gut bacterial taxa, including *Lachnospiraceae*, *Porphyromonadaceae*,
232 *Roseburia*, *RuminococcaceaeUCG004*, *DefluviitaleaceaeUCG011*, *Eubacterium*
233 (*brachy group*), and *Peptococcus*, were identified. Given previous studies suggest that
234 pre-existing autoimmune conditions such as inflammatory bowel disease, psoriasis,
235 and rheumatoid arthritis may predispose individuals to irAEs susceptibility (38,39).
236 We further examined the SNPs associated with the significant bacterial taxa using
237 PhenoScanner. Only one SNP (rs11597285) for the *Collinsella* genus was found to be
238 associated with allergic disease (e.g. allergic rhinitis and eczema) (refer to **Table S9**).
239 However, the results of *Collinsella* remained uninfluenced after removing rs11597285
240 in the LOO analysis (described below). The complete results of the primary MR
241 analysis can be found in **Table S2** and **Table S3**.

242

243 **3.2 Main MR results and sensitivity analysis for high-grade irAEs**

244 As shown in **Figure 2**, the IVW estimate suggested the abundance of
245 *Lachnospiraceae* family was associated with a shortened time to high-grade irAEs
246 (Beta = -1.22, 95% CI: -1.99 to -0.44, p = 2.17×10^{-3}), indicating *Lachnospiraceae*
247 serves as a risk factor for the development of high-grade irAEs. The deleterious effect
248 remained significant in pleiotropy-robust cML-MA-BIC estimation (Beta = -1.24, 95%
249 CI: -2.45 to -0.02, p = 4.62×10^{-2}). Surprisingly, *Ruminiclostridium6* genus was
250 significantly associated with an increased risk of high-grade irAEs in all MR
251 approaches, including IVW (Beta = -2.11, 95% CI: -2.98 to -1.23, p = 2.47×10^{-6}),
252 cML-MA-BIC (Beta = -2.17, 95% CI: -3.49 to -0.86, p = 1.19×10^{-3}), Weighted
253 median (Beta = -2.43, 95% CI: -4.05 to -0.81, p = 3.29×10^{-3}), and other methods. In
254 addition, the IVW estimate indicated a protective effect of the *Akkermansia* genus on
255 high-grade irAEs (Beta = 1.27, 95% CI: 0.28 to 2.25, p = 0.01), and this finding was
256 confirmed by the IVW estimate of its paternal taxon *Verrucomicrobiaceae* (Beta =
257 1.27, 95% CI: 0.29 to 2.25, p = 0.01). The IVW estimate of *Anaerostipes* genus also
258 indicated a suggestive protective effect against high-grade irAEs (Beta = 2.1, 95% CI:

259 0.85 to 3.35, $p = 1.02 \times 10^{-3}$), as well as cML-MA-BIC (Beta = 2.17, 95% CI: 0.57 to
260 3.77, $p = 7.88 \times 10^{-3}$). Moreover, significant effects of the *Coproccoccus3* (Beta =
261 -2.04, 95% CI: -2.7 to -1.39, $p = 8.93 \times 10^{-10}$), *Collinsella* (Beta = -1.12, 95% CI: -1.7
262 to -0.53, $p = 1.7 \times 10^{-4}$), and *Eubacterium (fissicatena group)* genus (Beta = -0.73, 95%
263 CI: -1.01 to -0.46, $p = 1.93 \times 10^{-7}$) were all revealed by IVW estimate, indicating an
264 increased risk of high-grade irAEs. Scatter plots reflecting the effect size of iVs on
265 both bacterial taxa and high-grade irAEs are shown in **Figure 4**.

266 In the subsequent analysis of heterogeneity and horizontal pleiotropy, Cochra's
267 Q statistics revealed no significant heterogeneity (p -value > 0.05) among the iVs for
268 the gut bacterial taxa in high-grade irAEs analysis (see **Table 1**). No significant
269 evidence for directional horizontal pleiotropy was found in the MR-Egger regression
270 intercept analysis and MR PRESSO global test (**Table 1 and Table S4**). Additionally,
271 the LOO analysis identified no predominant SNP that influenced the results (**Figure**
272 **6**). We further performed reverse MR analysis and demonstrated no reverse causation
273 exists between high-grade irAEs and the abundance of gut bacterial taxa (**Table S6**).
274

275 **3.3 Main MR results and sensitivity analysis for all-grade irAEs**

276 **Figure 3** reveals the association between bacterial taxa and all-grade irAEs. It is
277 noteworthy that the deleterious impact of the *Lachnospiraceae* family was also
278 detected in all-grade irAEs, as revealed by IVW (Beta = -2.05, 95% CI: -3.27 to -0.82,
279 $p = 1.06 \times 10^{-3}$), cML-MA-BIC (Beta = -2.21, 95% CI: -3.32 to -1.1, $p = 9.16 \times 10^{-5}$),
280 and Weighted median estimates (Beta = -1.72, 95% CI: -3.2 to -0.24, $p = 2.25 \times 10^{-2}$).
281 The IVW estimate of *Roseburia* genus also showed an increased risk of all-grade
282 irAEs (Beta = -2.07, 95% CI: -3.21 to -0.93, $p = 3.76 \times 10^{-4}$). Consistent results were
283 observed in ML (Beta = -2.07, 95% CI: -3.67 to -0.47, $p = 1.14 \times 10^{-2}$) and
284 cML-MA-BIC (Beta = -2.08, 95% CI: -3.71 to -0.45, $p = 1.23 \times 10^{-2}$) estimates. On
285 the contrary, *RuminococcaceaeUCG004* (Beta = 1.07, 95% CI: 0.43 to 1.72, $p = 1.05$
286 $\times 10^{-3}$) and *DefluviitaleaceaeUCG011* (Beta = 0.82, 95% CI: 0.38 to 1.25, $p = 2.15 \times$
287 10^{-4}) were identified to decrease the risk of all-grade irAEs according to the IVW
288 approach. Subsequently, the results for *RuminococcaceaeUCG004* were consistent
289 with the cML-MA-BIC (Beta = 1.1, 95% CI: 0.04 to 2.15, $p = 4.12 \times 10^{-2}$) and ML
290 method (Beta = 1.09, 95% CI: 0.04 to 2.14, $p = 4.16 \times 10^{-2}$). Moreover, the IVW
291 estimates suggested that *Porphyromonadaceae* (Beta = -1.11, 95% CI: -1.83 to -0.39,
292 $p = 2.46 \times 10^{-3}$), *Eubacterium (brachy group)* (Beta = -0.71, 95% CI: -1.14 to -0.27, p
293 $= 1.38 \times 10^{-3}$), and *Peptococcus* (Beta = -0.71, 95% CI: -1.24 to -0.18, $p = 8.82 \times 10^{-3}$)
294 may increase the risk of all-grade irAEs. Scatter plots reflecting the effect size of each
295 IV on both bacterial taxa and all-grade irAEs are shown in **Figure 5**.

296 Similarly, Cochran's Q statistics indicated an absence of notable heterogeneity in
297 the iVs of gut bacterial taxa (refer to **Table 1**). In addition, the results from the

298 MR-Egger regression intercept analysis and the MR PRESSO global test
299 demonstrated no significant evidence of directional horizontal pleiotropy (**Table 1**
300 **and Table S4**). Next, no significant single SNP was identified in the LOO analysis
301 that influenced the results (**Figure 7**). Overall, these results provide evidence for the
302 association between specific gut bacterial taxa and the development of high-grade and
303 all-grade irAEs, and highlight the potential role of the gut microbiota in irAEs.

304

305 **3.4 Multivariable MR analysis**

306 Given the strong correlation between body mass index (BMI) and gut microbiota
307 (40,41), we incorporated BMI and weight-associated anthropometric traits, as well as
308 several lifestyle risk factors associated with irAEs (42), into the univariable MR
309 analysis. Detailed GWAS datasets information of these anthropometric traits and
310 lifestyle risk factors can be found in **Table S10**. The univariable MR analysis
311 suggested a correlation between BMI and an increased risk of all-grade irAEs (**Table**
312 **2**). Thus, we performed subsequent MVMR analysis by including BMI as an
313 additional exposure alongside previously identified gut microbial taxa (**Table S11**).
314 Notably, after accounting for the effect of BMI in the MVMR analysis,
315 *Lachnospiraceae* still remained significantly associated with the risk of developing
316 all-grade irAEs (Beta = -1.07, 95% CI: -1.96 to -0.18, p = 0.02), and high-grade irAEs
317 (Beta = -0.91, 95% CI: -1.84 to 0.01, p = 0.05) with a marginal p value (**Table 3**).

318

319 **4. Discussion**

320 In this study, univariable bi-directional MR and MVMR analyses were
321 conducted to infer the causal association between gut microbiota and irAEs. We
322 identified fourteen gut bacterial taxa that were causally associated with high-grade
323 and all-grade irAEs. Surprisingly, *Lachnospiraceae* strong associated with an
324 increased risk of both irAEs phenotypes, even after accounting for the effect of BMI
325 in the MVMR analysis. Additionally, we found robust evidence indicating that
326 *Ruminiclostridium6* predisposes ICIs receivers to developing high-grade irAEs.
327 *Coprococcus3*, *Collinsella*, and *Eubacterium (fissicatena group)* were also associated
328 with an increased risk of high-grade irAEs, while *Akkermansia*, *Verrucomicrobiaceae*,
329 and *Anaerostipes* exhibited protective roles in high-grade irAEs. For all-grade irAEs,
330 *Porphyromonadaceae*, *Roseburia*, *Eubacterium (brachy group)*, and *Peptococcus*
331 were associated with an elevated risk, while *RuminococcaceaeUCG004* and
332 *DefluviitaleaceaeUCG011* were associated with a reduced risk.

333 Several observational studies have demonstrated associations between gut
334 microbiota and irAEs (11,17–19,43,44). *Lachnospiraceae* species (such as

335 *Coprococcus* and *Roseburia*), which are obligately anaerobic, variably spore-forming
336 bacteria, were found to correlate with increased risk of various types of irAEs
337 (17,18,45). In a more recent study, two species of the *Lachnospiraceae* family were
338 specifically enriched in irAEs that occur in endocrine organs (46). Consistent with
339 these findings, we also identified the *Lachnospiraceae* family, and its two genera (i.e.,
340 *Coprococcus* and *Roseburia*) associated with an increased risk of irAEs. Importantly,
341 the harmful influence of the *Lachnospiraceae* family was observed in high-grade
342 irAEs and all-grade irAEs, even after adjusting the effect of BMI, which provides
343 further validity and robustness to our study. *Ruminiclostridium* has been less studied
344 in irAEs, but some studies have observed its accumulation in a mouse model of
345 DSS-induced colitis. While treated with phloretin (a dihydrochalcone flavonoid) or
346 sodium butyrate (one of the short chain fatty acids [SCFAs]), both of which alleviates
347 DSS-induced colitis, the abundance of *Ruminiclostridium* was reduced (47,48). In
348 addition, the *Ruminiclostridium* genus has also been associated with
349 autoimmune-related diseases, such as the experimental multiple sclerosis model and
350 Alzheimer's disease (49,50). Based on our strong association of *Ruminiclostridium*
351 with increased risk of high-grade irAEs, it is suggested that *Ruminiclostridium* may
352 play a pivotal role in the development of autoimmune conditions and could be a
353 potential target for relieving irAEs symptoms, although more evidence is needed.

354 *Akkermansia muciniphila*, an anaerobic gram-negative species that belongs to
355 *Akkermansia* genus, and *Verrucomicrobiaceae* family, has gained much attention in
356 immunotherapy due to their association with a favorable response in ICIs therapy
357 (51–53). *Akkermansia muciniphila* has also been shown to exhibit a protective role in
358 ICIs-associated colitis (54). Mechanically, Wang et al. demonstrated that *Akkermansia*
359 *muciniphila* and its purified membrane protein mitigated colitis by regulating
360 macrophages and CD8+ T cells in the colon tissue (55). Our study further supported
361 the protective role of *Akkermansia* in high-grade irAEs. *Ruminococcaceae*, a key
362 family of bacteria producing short-chain fatty acids (SCFAs), has been observed to be
363 enriched in ICIs responders without severe irAEs (11). Previous studies have found
364 that *Faecalibacterium prausnitzii*, a species belonging to the *Ruminococcaceae* family,
365 was decreased in non-responders and those experiencing severe irAEs (11,17,45).
366 These findings suggest a potential role of *Ruminococcaceae* as protective bacteria,
367 possibly through the facilitation of SCFAs accumulation, in the mitigation of irAEs.
368 *Collinsella* and *Anaerostipes* have limited evidence in irAEs, but the *Collinsella*
369 genus has been reported to increase the production of IL-17A and enhance rheumatoid
370 arthritis severity (56). In contrast, *Anaerostipes*, which belongs to the
371 *Lachnospiraceae* family, was conversely associated with the risk of high-grade irAEs
372 in our study (11,18). These discrepancies observed in previous clinical studies might
373 be attributed to several factors, including limited sample sizes in previous

374 observational studies, heterogeneity among the samples, and inadequate exploration
375 of the taxonomic classification at the genus level of the gut microbiota. Therefore, a
376 more detailed taxonomy for gut microbiota is crucial in dissecting the underlying
377 mechanisms.

378 Gut microbiota plays a pivotal role in modulating human immune homeostasis,
379 and an imbalance in gut microbial composition, known as gut dysbiosis, has been
380 implicated in several autoimmune diseases (15,16,57). IrAEs resemble autoimmune
381 diseases in many aspects (38,58,59). Thus, despite the underlying mechanisms by
382 which gut microbiota manipulates the development of irAEs remain poorly
383 understood, we hypothesize that there might be some shared etiology of microbiota in
384 autoimmune diseases and irAEs. These mechanisms include: (1) “Molecular
385 mimicry”: Evidence has shown that exposure to homologous amino acid sequences or
386 epitopes of microbiota and aberrant activation of autoreactive B or T cells leads to
387 multiple autoimmune diseases, such as multiple sclerosis (60), Guillain–Barré
388 syndrome (61), Type 1 diabetes (62), Rheumatoid arthritis (63), and primary biliary
389 cholangitis (64), which is referred to as “molecular mimicry” (65). It is believed that
390 the systematic activation of the immune system during ICIs treatment triggers irAEs
391 by bypassing self-tolerance in normal organs. One intriguing fact is that most irAEs
392 occur in barrier organs (e.g., the intestinal tract, skin, and lungs) (58,66). This implies
393 that the activated immune response might target the commensal microbiome as
394 antigenic targets, although this hypothesis has not been fully demonstrated. (2)
395 Decreased accumulation of SCFAs: SCFAs, including acetate, propionate, and
396 butyrate, are a group of organic compounds primarily produced by the gut microbiota
397 during the fermentation of dietary fibers. These metabolites were shown to improve
398 the anti-cancer function of effector T cells, but they also seem to exhibit
399 anti-inflammatory characteristics (67,68). Butyrate, one of the well-studied SCFAs,
400 was shown to inhibit the activation of NF- κ B and its downstream pathway (69),
401 thereby reducing the production of pro-inflammatory cytokines such as IL-8 (70),
402 while increasing the levels of anti-inflammatory factors like IL-10 (71). Moreover,
403 SCFAs serve as a key energy source for colonocytes and maintain intestinal barrier
404 integrity (72). Thus, the reduced abundance of SCFAs-producing bacteria along with
405 its metabolites may participate in the development of irAEs. (3) Other mechanisms:
406 Stimulation of the immune response by microbial-associated molecular patterns (e.g.,
407 include lipopolysaccharides (LPS), lipoproteins, flagellin and bacterial DNA) (73)
408 and compromised vitamin B and polyamine metabolism that associated with gut
409 dysbiosis (19) may also contribute to irAEs.

410 Taken together, the gut microbiota and the human immune system maintain a
411 delicate balance under normal physiological conditions. Once the balance has been
412 disturbed (e.g., ICIs treatment), the dysregulated microbiota might lead to the

413 development of undesirable irAEs. The primary management strategy for irAEs (>
414 grade 2) involves the suspension of ICIs and/or utilizing immunosuppressive therapy
415 (74). Nevertheless, one concern is that discontinuing ICIs or using
416 immunosuppressants may compromise treatment efficacy. Ideally, approaches to
417 boost ICIs efficacy while reducing the accompanied irAEs are to be expected in the
418 future. FMT, an approach to modulate gut microbiota, has been shown to increase
419 ICIs efficacy in melanoma patients (75,76), and emerging evidence has demonstrated
420 the mitigation of ICIs-related colitis through FMT in clinical practice (77).
421 Interestingly, while irAEs and ICIs efficacy are often considered two sides of the
422 same coin, certain gut bacteria, such as *Akkermansia muciniphila* and
423 *Faecalibacterium prausnitzii*, have been shown to ameliorate irAEs and reinforce
424 ICIs efficacy at the same time (78). This suggests that targeting gut microbiota could
425 be an ideal approach to relieve irAEs symptoms and maintain ICIs efficacy, but
426 further real-world evidence is needed to support this hypothesis.

427 Our study possesses several strengths. Firstly, we applied the MR approach to
428 infer the causal associations between gut microbiota and irAEs, which effectively
429 mitigates the influence of confounding factors and provides robust causal inference.
430 Secondly, we conducted reverse MR analyses, confirming the absence of reverse
431 causation, thereby enhancing the validity of our study. Thirdly, we applied MVMR in
432 our analysis which further strengthened the validity and robustness of our study.
433 Moreover, we incorporated several pleiotropy-robust methods such as MR PRESSO
434 and cML-MA-BIC, further strengthening the robustness of our study. However, there
435 are also certain inherent limitations in our study that should be considered when
436 interpreting the findings. Firstly, our analysis is based on European-derived GWAS
437 summary statistics, which might confine the generalization of the findings to other
438 populations. Secondly, due to the utilization of summary statistics instead of raw data
439 in the analysis, subgroup analyses based on ICIs regimes (e.g. PD-1/PD-L1 group,
440 CTLA-4 group, and combined therapy group) could not be performed. Thirdly, the gut
441 microbiota is shaped by multiple environmental factors, which confines the number of
442 the identified significant gene loci in the GWAS (26). Thus, we relaxed the significant
443 threshold of iVs to 1×10^{-5} (29) and employed Bonferroni correction to mitigate
444 potential false positive results.

445

446 **5. Conclusion**

447 In conclusion, our univariable and multivariable MR analysis identified a strong
448 causal association between *Lachnospiraceae* and irAEs, along with several other gut
449 microbial taxa, such as *Akkermansia* and *Ruminiclostridium6* etc.. However, whether
450 the FMT or probiotics could be used as interventional approaches to mitigate irAEs

451 while reserving ICIs efficacy, additional randomized clinical trials (RCTs) are
452 warranted. Furthermore, in-depth investigations are needed to elucidate the precise
453 mechanisms through which the gut microbiota influences the development of irAEs.

454

455 **Declarations**

456 **Acknowledgment:**

457 We acknowledge all the investigators who have made their GWAS data available.

458

459 **Author contributions**

460 B. L. conceptualized this study. B. L., Z. L., and T. J. were involved in the analyses
461 and manuscript drafting of this study. X. G. and X. Z. were involved in the data
462 curation. B. L., T. J. X. Y., Z. C., and L. D. were involved in the interpretation of the
463 methodology and results. B. L. and Z. L. were involved in the visualization of the
464 results. B. Z. was involved in obtaining funding and critical revision of the
465 manuscript.

466

467 **Funding:**

468 This study was supported by the National Nature Science Foundations of China
469 (Grant number 82203108), China Postdoctoral Science Foundation (Grant number
470 2022M722275), and the Key R&D Program of Sichuan Province, China (Grant
471 number 2023YFS0278).

472

473 **Conflict of Interest:**

474 All authors declare no conflict of interest.

475

476 **Data Availability:**

477 This study was conducted using public-available data. The GWAS summary statistics
478 for gut microbiota are available at www.mibiogen.org, and GWAS summary statistics
479 for irAEs are available at <https://zenodo.org/record/6800429>.

480

481

482 **Supplementary Information**

483 **Table S1.** All Instrumental variables used for gut microbiota in the MR analysis.

484 **Table S2.** Full results of primary MR analysis between bacterial taxa and all-grade
485 irAEs.

486 **Table S3.** Full results of primary MR analysis between bacterial taxa and high-grade
487 irAEs.

488 **Table S4.** Results of MR PRESS Global test.

489 **Table S5.** Instrumental variables for irAEs in the reverse MR analysis.

490 **Table S6.** Results of reverse MR analysis between all-grade irAEs and the identified
491 significant gut bacterial taxa.

492 **Table S7.** Results of reverse MR analysis between high-grade irAEs and the identified
493 significant gut bacterial taxa.

494 **Table S8.** Results of heterogeneity and horizontal pleiotropy analysis in reverse MR
495 analysis.

496 **Table S9.** PhenoScanner results of instrumental variables used for significant bacterial
497 taxa in the MR analysis.

498 **Table S10.** Description of datasets used for weight-associated anthropometric and
499 lifestyle factors in univariable MR analysis.

500 **Table S11.** Multivariate MR estimates between gut microbiota (adjusted for BMI) and
501 irAEs.

502

503

Table 1. Results of heterogeneity and horizontal pleiotropy analysis.

bacterial taxa (exposure)	irAEs (outcome)	Heterogeneity test			Horizontal pleiotropy results		
		Cochran's Q	df	p-value	Egger intercept	SE	p-value
<i>Lachnospiraceae</i>	High-grade irAEs	5.18	12	0.95	0.04	0.11	0.73
<i>Verrucomicrobiaceae</i>	High-grade irAEs	4.18	7	0.76	0.36	0.61	0.57
<i>Eubacterium (fissicatena group)</i>	High-grade irAEs	0.33	4	0.99	0.07	0.53	0.9
<i>Akkermansia</i>	High-grade irAEs	4.18	7	0.76	0.37	0.61	0.56
<i>Anaerostipes</i>	High-grade irAEs	4.13	6	0.66	0.38	0.2	0.11
<i>Collinsella</i>	High-grade irAEs	0.82	6	0.99	-0.19	0.23	0.43
<i>Coprococcus3</i>	High-grade irAEs	0.47	4	0.98	-0.28	0.46	0.59
<i>Ruminiclostridium6</i>	High-grade irAEs	3.54	7	0.83	-0.17	0.18	0.38
<i>Lachnospiraceae</i>	All-grade irAEs	17.3	12	0.14	0.09	0.11	0.43
<i>Porphyromonadaceae</i>	All-grade irAEs	0.66	4	0.96	0.05	0.28	0.87
<i>Eubacterium (brachy group)</i>	All-grade irAEs	1.41	5	0.92	-0.11	0.29	0.73
<i>DefluviitaleaceaeUCG011</i>	All-grade irAEs	0.48	4	0.98	-0.03	0.25	0.92
<i>Peptococcus</i>	All-grade irAEs	1.87	5	0.87	-0.12	0.24	0.66
<i>Roseburia</i>	All-grade irAEs	3.75	7	0.81	-0.31	0.22	0.21
<i>RuminococcaceaeUCG004</i>	All-grade irAEs	2.73	7	0.91	-0.23	0.3	0.47

df, degree of freedom; SE, standard error.

504

505

Table 2. Univariate MR estimates between common risk factors and irAEs.

Exposures	Method	NSNP	Outcomes				
			High-grade irAEs		All-grade irAEs		
			Beta (95%CI)	p-value	Beta (95%CI)	p-value	
Anthropometric factors							
BMI	IVW	314	-0.60 (-1.34, 0.14)	0.11	-0.74 (-1.41, -0.06)	0.03	
Waist circumference	IVW	26	0.61 (-1.01, 2.23)	0.46	0.05 (-1.15, 1.24)	0.94	
Waist circumference (adjusted for BMI)	IVW	46	0.00 (-1.37, 1.38)	1.00	-0.39 (-1.5, 0.73)	0.50	
Hip circumference	IVW	38	0.09 (-0.92, 1.10)	0.86	-0.63 (-1.7, 0.44)	0.25	
Hip circumference (adjusted for BMI)	IVW	52	0.65 (-0.38, 1.69)	0.21	0.47 (-0.52, 1.45)	0.35	
Waist-to-hip ratio	IVW	20	-0.28 (-2.21, 1.64)	0.77	-1.69 (-3.56, 0.18)	0.08	
Waist-to-hip ratio (adjusted for BMI)	IVW	25	0.84 (-0.88, 2.55)	0.34	-0.54 (-1.94, 0.85)	0.44	
Lifestyle factors							
Alcoholic drinks per week	IVW	14	-0.44 (-4.21, 3.33)	0.82	-0.06 (-3.24, 3.12)	0.97	
Cigarettes smoked per day	IVW	13	0.11 (-0.93, 1.16)	0.83	0.67 (-0.29, 1.63)	0.17	
Smoking initiation	IVW	54	0.08 (-1.21, 1.37)	0.90	-0.10 (-1.23, 1.04)	0.87	
Type 2 diabetes	IVW	79	-0.16 (-0.48, 0.17)	0.34	0.01 (-0.33, 0.34)	0.97	

BMI, body mass index; IVW, Inverse variance weighted method; NSNP, number of SNPs; irAEs, immune-related adverse events; 95%CI, 95% confidential interval.

509

Table 3. Multivariable MR estimates between *Lachnospiraceae*, BMI and irAEs.

Exposures in MVMR	Outcomes			
	High-grade irAEs		All-grade irAEs	
	Beta (95%CI)	p-value	Beta (95%CI)	p-value
<i>Lachnospiraceae</i>	-0.91 (-1.84, 0.01)	0.05	-1.07 (-1.96, -0.18)	0.02
BMI	-0.43 (-1.2, 0.34)	0.28	0.01 (-0.33, 0.34)	0.34

MVMR, multivariable MR analysis; BMI, body mass index; irAEs, immune-related adverse events; 95%CI, 95% confidential interval.

510

511

512

513

514 **References:**

- 515 1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade.
516 Science. 2018 Mar 23;359(6382):1350–5.
- 517 2. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.
518 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J
519 Med. 2010 Aug 19;363(8):711–23.
- 520 3. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al.
521 Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med.
522 2015 Nov 5;373(19):1803–13.
- 523 4. Mj O, R M, Ji L, S L, Hj L, Ma M, et al. Nivolumab in patients with metastatic
524 DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer
525 (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol [Internet].
526 2017 Sep [cited 2023 Feb 17];18(9). Available from:
527 <https://pubmed.ncbi.nlm.nih.gov/28734759/>
- 528 5. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et
529 al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N
530 Engl J Med. 2018 May 31;378(22):2078–92.
- 531 6. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat
532 Commun. 2020 Jul 30;11(1):3801.
- 533 7. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et
534 al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J
535 Med. 2015 May 21;372(21):2006–17.
- 536 8. Suresh K, Naidoo J. Lower Survival in Patients Who Develop Pneumonitis
537 Following Immunotherapy for Lung Cancer. Clin Lung Cancer. 2020 May
538 1;21(3):e169–70.
- 539 9. Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R,
540 Rutkowski P, et al. Efficacy and Safety Outcomes in Patients With Advanced
541 Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because
542 of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin
543 Oncol Off J Am Soc Clin Oncol. 2017 Dec 1;35(34):3807–14.
- 544 10. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et
545 al. Management of Immune-Related Adverse Events in Patients Treated With
546 Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology
547 Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2018 Jun
548 10;36(17):1714–68.
- 549 11. Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, et al.
550 Diet-driven microbial ecology underpins associations between cancer immunotherapy
551 outcomes and the gut microbiome. Nat Med. 2022 Nov;28(11):2344–52.
- 552 12. Jing Y, Chen X, Li K, Liu Y, Zhang Z, Chen Y, et al. Association of antibiotic
553 treatment with immune-related adverse events in patients with cancer receiving
554 immunotherapy. J Immunother Cancer. 2022 Jan;10(1):e003779.
- 555 13. Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, et al.

- 556 Impact of antibiotic therapy on the development and response to treatment of immune
557 checkpoint inhibitor-mediated diarrhea and colitis. *J Immunother Cancer*. 2019 Sep
558 5;7(1):242.
- 559 14. Mohiuddin JJ, Chu B, Facciabene A, Poirier K, Wang X, Doucette A, et al.
560 Association of Antibiotic Exposure With Survival and Toxicity in Patients With
561 Melanoma Receiving Immunotherapy. *J Natl Cancer Inst*. 2021 Feb 1;113(2):162–70.
- 562 15. Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI. Gut Microbiota and
563 Immune System Interactions. *Microorganisms*. 2020 Oct 15;8(10):1587.
- 564 16. Belkaid Y, Hand T. Role of the Microbiota in Immunity and inflammation. *Cell*.
565 2014 Mar 27;157(1):121–41.
- 566 17. Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al.
567 Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma
568 patients treated with ipilimumab. *Ann Oncol Off J Eur Soc Med Oncol*. 2017 Jun
569 1;28(6):1368–79.
- 570 18. McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, et al.
571 Intestinal microbiota signatures of clinical response and immune-related adverse
572 events in melanoma patients treated with anti-PD-1. *Nat Med*. 2022
573 Mar;28(3):545–56.
- 574 19. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal
575 microbiome analyses identify melanoma patients at risk for
576 checkpoint-blockade-induced colitis. *Nat Commun*. 2016 Feb 2;7:10391.
- 577 20. Bajinka O, Tan Y, Abdelhalim KA, Özdemir G, Qiu X. Extrinsic factors
578 influencing gut microbes, the immediate consequences and restoring eubiosis. *AMB*
579 *Express*. 2020 Jul 25;10(1):130.
- 580 21. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. *Lancet*
581 *Lond Engl*. 1986 Mar 1;1(8479):507–8.
- 582 22. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation
583 studies: a guide, glossary, and checklist for clinicians. *BMJ*. 2018 Jul 12;362:k601.
- 584 23. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal
585 inference in epidemiological studies. *Hum Mol Genet*. 2014 Sep 15;23(R1):R89–98.
- 586 24. Chen L, Peters JE, Prins B, Persyn E, Traylor M, Surendran P, et al. Systematic
587 Mendelian randomization using the human plasma proteome to discover potential
588 therapeutic targets for stroke. *Nat Commun*. 2022 Oct 17;13:6143.
- 589 25. Zhang X, Theodoratou E, Li X, Farrington SM, Law PJ, Broderick P, et al.
590 Genetically predicted physical activity levels are associated with lower colorectal
591 cancer risk: a Mendelian randomisation study. *Br J Cancer*. 2021 Mar;124(7):1330–8.
- 592 26. Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J,
593 Demirkan A, et al. Large-scale association analyses identify host factors influencing
594 human gut microbiome composition. *Nat Genet*. 2021 Feb;53(2):156–65.
- 595 27. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, et al.
596 Germline variants associated with toxicity to immune checkpoint blockade. *Nat Med*.
597 2022 Dec;28(12):2584–91.
- 598 28. Liu X, Tong X, Zou Y, Lin X, Zhao H, Tian L, et al. Mendelian randomization
599 analyses support causal relationships between blood metabolites and the gut

- 600 microbiome. *Nat Genet.* 2022 Jan;54(1):52–61.
- 601 29. Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Vösa U, et al.
602 Causal relationships among the gut microbiome, short-chain fatty acids and metabolic
603 diseases. *Nat Genet.* 2019 Apr;51(4):600–5.
- 604 30. Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, et al. Recent
605 Developments in Mendelian Randomization Studies. *Curr Epidemiol Rep.*
606 2017;4(4):330–45.
- 607 31. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al.
608 Guidelines for performing Mendelian randomization investigations. *Wellcome Open*
609 *Res.* 2019;4:186.
- 610 32. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal
611 pleiotropy in causal relationships inferred from Mendelian randomization between
612 complex traits and diseases. *Nat Genet.* 2018 May;50(5):693–8.
- 613 33. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple
614 instrumental variables in Mendelian randomization: comparison of allele score and
615 summarized data methods. *Stat Med.* 2016 May 20;35(11):1880–906.
- 616 34. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
617 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
618 Estimator. *Genet Epidemiol.* 2016 May;40(4):304–14.
- 619 35. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data
620 Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol.*
621 2017 Dec 1;46(6):1985–98.
- 622 36. Xue H, Shen X, Pan W. Constrained maximum likelihood-based Mendelian
623 randomization robust to both correlated and uncorrelated pleiotropic effects. *Am J*
624 *Hum Genet.* 2021 Jul 1;108(7):1251–69.
- 625 37. Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and
626 pleiotropic instruments in two-sample multivariable Mendelian randomization. *Stat*
627 *Med.* 2021 Nov 10;40(25):5434–52.
- 628 38. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al.
629 Management of immune checkpoint blockade dysimmune toxicities: a collaborative
630 position paper. *Ann Oncol Off J Eur Soc Med Oncol.* 2016 Apr;27(4):559–74.
- 631 39. Plaçais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, et al. Risk of
632 irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors
633 for stage III or IV melanoma: results from a matched case–control study. *Ann Rheum*
634 *Dis.* 2022 Oct 1;81(10):1445–52.
- 635 40. Stanislawski MA, Dabelea D, Lange LA, Wagner BD, Lozupone CA. Gut
636 microbiota phenotypes of obesity. *NPJ Biofilms Microbiomes.* 2019;5(1):18.
- 637 41. Deng K, Shuai M, Zhang Z, Jiang Z, Fu Y, Shen L, et al. Temporal relationship
638 among adiposity, gut microbiota, and insulin resistance in a longitudinal human
639 cohort. *BMC Med.* 2022 May 19;20(1):171.
- 640 42. Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk Factors
641 and Biomarkers for Immune-Related Adverse Events: A Practical Guide to
642 Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
643 *Front Immunol [Internet].* 2022 [cited 2023 Sep 12];13. Available from:

- 644 <https://www.frontiersin.org/articles/10.3389/fimmu.2022.779691>
- 645 43. Liu T, Xiong Q, Li L, Hu Y. Intestinal microbiota predicts lung cancer patients at
646 risk of immune-related diarrhea. *Immunotherapy*. 2019 Apr;11(5):385–96.
- 647 44. Chau J, Yadav M, Liu B, Furqan M, Dai Q, Shahi S, et al. Prospective correlation
648 between the patient microbiome with response to and development of
649 immune-mediated adverse effects to immunotherapy in lung cancer. *BMC Cancer*.
650 2021 Jul 13;21(1):808.
- 651 45. Liu W, Ma F, Sun B, Liu Y, Tang H, Luo J, et al. Intestinal Microbiome
652 Associated With Immune-Related Adverse Events for Patients Treated With
653 Anti-PD-1 Inhibitors, a Real-World Study. *Front Immunol*. 2021 Dec 16;12:756872.
- 654 46. Zhang Y, Cheng S, Zou H, Han Z, Xie T, Zhang B, et al. Correlation of the gut
655 microbiome and immune-related adverse events in gastrointestinal cancer patients
656 treated with immune checkpoint inhibitors. *Front Cell Infect Microbiol* [Internet].
657 2023 [cited 2023 Jun 18];13. Available from:
658 <https://www.frontiersin.org/articles/10.3389/fcimb.2023.1099063>
- 659 47. Dou X, Gao N, Yan D, Shan A. Sodium Butyrate Alleviates Mouse Colitis by
660 Regulating Gut Microbiota Dysbiosis. *Anim Open Access J MDPI*. 2020 Jul
661 7;10(7):1154.
- 662 48. Wu M, Li P, An Y, Ren J, Yan D, Cui J, et al. Phloretin ameliorates dextran
663 sulfate sodium-induced ulcerative colitis in mice by regulating the gut microbiota.
664 *Pharmacol Res*. 2019 Dec;150:104489.
- 665 49. Johanson DM, Goertz JE, Marin IA, Costello J, Overall CC, Gaultier A.
666 Experimental autoimmune encephalomyelitis is associated with changes of the
667 microbiota composition in the gastrointestinal tract. *Sci Rep*. 2020 Sep
668 16;10(1):15183.
- 669 50. Ning J, Huang SY, Chen SD, Zhang YR, Huang YY, Yu JT. Investigating Casual
670 Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases:
671 A Mendelian Randomization Study. *J Alzheimers Dis JAD*. 2022;87(1):211–22.
- 672 51. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut
673 microbiome influences efficacy of PD-1–based immunotherapy against epithelial
674 tumors. *Science*. 2018 Jan 5;359(6371):91–7.
- 675 52. Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, et al.
676 Cross-cohort gut microbiome associations with immune checkpoint inhibitor response
677 in advanced melanoma. *Nat Med*. 2022 Mar;28(3):535–44.
- 678 53. Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal
679 *Akkermansia muciniphila* predicts clinical response to PD-1 blockade in patients with
680 advanced non-small-cell lung cancer. *Nat Med*. 2022 Feb;28(2):315–24.
- 681 54. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL,
682 et al. Fecal microbiota transplantation for refractory immune checkpoint
683 inhibitor-associated colitis. *Nat Med*. 2018 Dec;24(12):1804–8.
- 684 55. Wang L, Tang L, Feng Y, Zhao S, Han M, Zhang C, et al. A purified membrane
685 protein from *Akkermansia muciniphila* or the pasteurised bacterium blunts colitis
686 associated tumorigenesis by modulation of CD8+ T cells in mice. *Gut*. 2020
687 Nov;69(11):1988–97.

- 688 56. Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, et al. An
689 expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis.
690 *Genome Med.* 2016 Apr 21;8(1):43.
- 691 57. Miyauchi E, Shimokawa C, Steimle A, Desai MS, Ohno H. The impact of the gut
692 microbiome on extra-intestinal autoimmune diseases. *Nat Rev Immunol.* 2023
693 Jan;23(1):9–23.
- 694 58. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse
695 effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
696 *Nat Rev Clin Oncol.* 2019 Sep;16(9):563–80.
- 697 59. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events
698 Associated with Immune Checkpoint Blockade. *N Engl J Med.* 2018 Jan
699 11;378(2):158–68.
- 700 60. Du C, Yao SY, Ljunggren-Rose Å, Sriram S. Chlamydia pneumoniae Infection of
701 the Central Nervous System Worsens Experimental Allergic Encephalitis. *J Exp Med.*
702 2002 Dec 16;196(12):1639–44.
- 703 61. Rodríguez Y, Rojas M, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C,
704 Monsalve DM, et al. Guillain–Barré syndrome, transverse myelitis and infectious
705 diseases. *Cell Mol Immunol.* 2018 Jun;15(6):547–62.
- 706 62. Gülden E, Wong FS, Wen L. The gut microbiota and Type 1 Diabetes. *Clin*
707 *Immunol.* 2015 Aug 1;159(2):143–53.
- 708 63. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al.
709 Antibodies to citrullinated α -enolase peptide 1 are specific for rheumatoid arthritis
710 and cross-react with bacterial enolase. *Arthritis Rheum.* 2008;58(10):3009–19.
- 711 64. Tanaka A, Leung PSC, Gershwin ME. Pathogen infections and primary biliary
712 cholangitis. *Clin Exp Immunol.* 2019 Jan 1;195(1):25–34.
- 713 65. Rojas M, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y,
714 Ramírez-Santana C, et al. Molecular mimicry and autoimmunity. *J Autoimmun.* 2018
715 Dec;95:100–23.
- 716 66. Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from
717 checkpoint inhibitors. *Trends Cancer.* 2023 Jul 1;9(7):543–53.
- 718 67. Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al. Short-chain
719 fatty acids induce both effector and regulatory T cells by suppression of histone
720 deacetylases and regulation of the mTOR–S6K pathway. *Mucosal Immunol.* 2015
721 Jan;8(1):80–93.
- 722 68. Luu M, Riester Z, Baldrich A, Reichardt N, Yuille S, Buseti A, et al. Microbial
723 short-chain fatty acids modulate CD8+ T cell responses and improve adoptive
724 immunotherapy for cancer. *Nat Commun.* 2021 Jul 1;12(1):4077.
- 725 69. Zhou G, Zhang N, Meng K, Pan F. Interaction between gut microbiota and
726 immune checkpoint inhibitor-related colitis. *Front Immunol.* 2022 Oct
727 27;13:1001623.
- 728 70. BÖCKER U, NEBE T, HERWECK F, HOLT L, PANJA A, JOBIN C, et al.
729 Butyrate modulates intestinal epithelial cell-mediated neutrophil migration. *Clin Exp*
730 *Immunol.* 2003 Jan;131(1):53–60.
- 731 71. Lee C, Kim BG, Kim JH, Chun J, Im JP, Kim JS. Sodium butyrate inhibits the

- 732 NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental
733 colitis in an IL-10 independent manner. *Int Immunopharmacol.* 2017 Oct;51:47–56.
- 734 72. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM.
735 The role of short-chain fatty acids in the interplay between diet, gut microbiota, and
736 host energy metabolism. *J Lipid Res.* 2013 Sep;54(9):2325–40.
- 737 73. Wang Y, Jenq RR, Wargo JA, Watowich SS. Microbiome influencers of
738 checkpoint blockade-associated toxicity. *J Exp Med.* 2023 Mar 6;220(3):e20220948.
- 739 74. Schneider BJ, Naidoo J, Santomaso BD, Lacchetti C, Adkins S, Anadkat M, et al.
740 Management of Immune-Related Adverse Events in Patients Treated With Immune
741 Checkpoint Inhibitor Therapy: ASCO Guideline Update. *J Clin Oncol.* 2021 Dec
742 20;39(36):4073–126.
- 743 75. Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison
744 RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in
745 melanoma patients. *Science.* 2021 Feb 5;371(6529):595–602.
- 746 76. Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al.
747 Fecal microbiota transplant promotes response in immunotherapy-refractory
748 melanoma patients. *Science.* 2021 Feb 5;371(6529):602–9.
- 749 77. Chen M, Liu M, Li C, Peng S, Li Y, Xu X, et al. Fecal Microbiota
750 Transplantation Effectively Cures a Patient With Severe Bleeding Immune
751 Checkpoint Inhibitor-Associated Colitis and a Short Review. *Front Oncol.* 2022 Jun
752 10;12:913217.
- 753 78. Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al.
754 Enterocolitis due to immune checkpoint inhibitors: a systematic review. *Gut.* 2018
755 Nov 1;67(11):2056–67.

756

757 **Figure legends:**

758 **Figure 1.** Overview of the study design.

759 Initially, IVs were selected from the summary GWAS data of the gut microbiota and
760 irAEs. Subsequently, by employing thresholds of p-value (IVW) < 0.05 and p-value
761 (MR PRESSO) < 0.05, the identified gut microbiota that exhibited statistically
762 significant associations were taken into further analysis. irAEs = immune-related
763 adverse events; ICIs = immune checkpoint inhibitors; BMI = body mass index; WC =
764 Waist circumference; HP = Hip circumference; WHR = Waist-to-hip ratio. (Created
765 with BioRender.com).

766 **Figure 2.** Forest plots of MR results for the causal association between the identified
767 eight gut microbial taxa and high-grade irAEs (grade 3 to 5 events). NSNP = number
768 of SNPs; Beta = effect size from the exposure to the outcome; CI = confidence
769 interval.

770 **Figure 3.** Forest plots of MR results for the causal association between the identified
771 seven gut microbial taxa and all-grade irAEs (grade 1 to 5 events). NSNP = number of
772 SNPs; Beta = effect size from the exposure to the outcome; CI = confidence interval.

773 **Figure 4.** Scatter plots of MR analysis between the gut microbial taxa and high-grade
774 irAEs (grade 3 to 5 events).

775 **Figure 5.** Scatter plots of MR analysis between the gut microbial taxa and all-grade
776 irAEs (grade 1 to 5 events).

777 **Figure 6.** Leave-one-out plots of MR analysis between the gut microbial taxa and
778 high-grade irAEs (grade 3 to 5 events).


779 **Figure 7.** Leave-one-out plots of MR analysis between the gut microbial taxa and
780 all-grade irAEs (grade 1 to 5 events).

781

782 **Figure S1.** Illustration of MR assumptions


783

Gut microbiota





Over 18,000 participants
132 bacterial taxa
(104 genera and 28 families)

irAEs



1751 participants
Among which 259 and 339 cancer patients experienced high-grade and all-grade irAEs during ICIs therapy



Univariable bi-directional MR analysis

Primary univariable MR analysis
IVs selection criteria: $p < 1 \times 10^{-5}$
clump ($r^2 = 0.001$, windows size = 10000 kb)

$p\text{-value}_{IVW} < 0.05$ ↓ $p\text{-value}_{MR_PRESSO} < 0.05$

Reverse MR and sensitivity analysis for **significant bacterial taxa**
(Maximum likelihood, Weighted Median, Weighted Mode, cML-MA-BIC, heterogeneity, and horizontal pleiotropy analysis, et al.)

Anthropometric traits
BMI, WC, HP, WHR,
WC (adjusted for BMI),
HP (adjusted for BMI),
WHR (adjusted for BMI)

Lifestyle factors
Alcohol consumption
Smoking behavior
Type 2 diabetes

Associated with irAEs

Identified bacterial taxa:

Lachnospiraceae
Verrucomicrobiaceae
Akkermansia
Ruminiclostridium6 et al.




Multivariable MR analysis


High-grade irAEs

Family level

Lachnospiraceae




Verrucomicrobiaceae




Genus level


Ruminiclostridium6




Coprococcus3




Anaerostipes




Akkermansia



Collinsella




Eubacterium (fissicatena group)




All-grade irAEs

Family level

Lachnospiraceae




Porphyromonadaceae




Genus level


Roseburia




Ruminococcaceae UCG004




Defluviitaleaceae UCG011



Eubacterium (brachy group)




Peptococcus





High-grade irAEs

Family level

Lachnospiraceae




Verrucomicrobiaceae




Genus level


Ruminiclostridium6



Coprococcus3




Anaerostipes




medRxiv preprint doi: <https://doi.org/10.1101/2023.07.24.23292742>; this version posted September 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).


Akkermansia



Collinsella




Eubacterium (*fissicatena* group)





All-grade irAEs

Family level

Lachnospiraceae




Porphyromonadaceae




Genus level


Roseburia




*Ruminococcaceae*UCG004




*Defluviitaleaceae*UCG011



Eubacterium (brachy group)




Peptococcus




High-grade irAEs

Family level

Lachnospiraceae




Verrucomicrobiaceae




Genus level


Ruminiclostridium6




Coprococcus3




Anaerostipes




Akkermansia



Collinsella



Eubacterium (fissicatena group)




bioRxiv preprint doi: <https://doi.org/10.1101/2021.07.24.242024>; this version posted September 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.


All-grade irAEs

Family level

Lachnospiraceae




Porphyromonadaceae




Genus level


Roseburia




Ruminococcaceae UCG004




Defluviitaleaceae UCG011



Eubacterium (brachy group)



Peptococcus



bioRxiv preprint doi: <https://doi.org/10.1101/2021.07.24.242024>; this version posted September 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.

